[Remote] Contract Lifecycle Management Capability Owner at Illumina

California Twp, Michigan, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Genomic Technology, Biotechnology, HealthcareIndustries

Skills

Key technologies and capabilities for this role

Contract Lifecycle Management (CLM)Conga CLMConga CPQProduct Backlog ManagementUser AdoptionRevenue GenerationOperational EfficiencyStakeholder CollaborationSales Processes

Questions & Answers

Common questions about this position

What is the employment type for this position?

This is a full-time position.

Is this role remote or does it require office work?

This information is not specified in the job description.

What key skills and experience are required for the CLM Capability Owner role?

The role requires a deep understanding of Contract Lifecycle Management principles, hands-on experience with Conga CLM and CPQ, and the ability to drive user adoption across diverse internal teams.

What is the company culture like at Illumina?

Illumina fosters a culture where every person in every role has the opportunity to make a difference, surrounded by extraordinary people, inspiring leaders, and world-changing projects.

What makes a strong candidate for this CLM Capability Owner position?

A strong candidate will have deep expertise in Conga CLM and CPQ, experience in product backlog management and Agile leadership, and the ability to collaborate with cross-functional teams like sales, legal, and finance to drive user adoption.

Illumina

Supports genomics startups through funding and resources

About Illumina

Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.

San Diego, CaliforniaHeadquarters

1998Year Founded

$27.2MTotal Funding

IPOCompany Stage

Venture Capital, BiotechnologyIndustries

5,001-10,000Employees

Risks

Over-reliance on NVIDIA's AI technology may limit flexibility in AI solution adoption.

Standardizing proteomics data across platforms could challenge Illumina's data reliability.

Single-flow-cell NovaSeq X System might cannibalize sales of higher-end models.

Differentiation

Illumina leads in genomic sequencing with advanced AI integration and multiomic data analysis.

The company offers innovative array-based solutions for DNA, RNA, and protein analysis.

Illumina's global expansion includes a new Global Capability Center in Bengaluru.

Upsides

Collaboration with NVIDIA enhances drug discovery and clinical development through AI integration.

Pilot proteomics program with UK Biobank aims to generate crucial reference datasets.

Single-cell sequencing kits make high-throughput sequencing accessible to smaller labs.

Land your dream remote job 3x faster with AI

Try Jobo Free